Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
  • Subscribe
Submit An Article

Latest Articles

  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler
    • News

  • Crude falls below $90 US a barrel for the first time since Feb
    Crude falls below $90 US a barrel for the first time since Feb
    • Market Update

  • Buddy Technologies deemed worthless as receivers gut the company, acknowledge shortfall on secured debt
    Buddy Technologies deemed worthless as receivers gut the company, acknowledge shortfall on secured debt
    • News

  • Allegra’s 3D printed bone replacement proves safe for animals
    Allegra’s 3D printed bone replacement proves safe for animals
    • News

  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved
    Getting things from A to B isn’t as simple as it seems, until Yojee gets involved
    • News

  • Revasum makes leadership change amid cash flow struggles and semiconductor shipping delays
    Revasum makes leadership change amid cash flow struggles and semiconductor shipping delays
    • News

  • Markets remain bullish on earnings, but can the upward momentum last?
    Markets remain bullish on earnings, but can the upward momentum last?
    • Market Update

  • July 2022 Economic Wrap and the ASX Stocks that Moved
    July 2022 Economic Wrap and the ASX Stocks that Moved
    • Opinion

  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident
    NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident
    • News

  • Propel taps into booming pet funerals demand with crematorium acquisitions
    Propel taps into booming pet funerals demand with crematorium acquisitions
    • News

Positive clinical trial results for nutritional shake bolsters $5m cap raise

  • In News
  • September 2, 2021
  • Samantha Freidin
Positive clinical trial results for nutritional shake bolsters $5m cap raise

Days after raising $5 million via a capital raise to accelerate their global strategy, Nutritional Growth Solutions (ASX: NGS) has released clinical trial data showing positive results for their product Healthy Heights Grow Daily Boys 10+. 

Just one of their growing range of products, Nutritional Growth Solutions creates clinically tested nutritional supplements for children, a surprisingly overlooked corner of the supplementation market. 

Backed by 20 years of research into paediatric nutrition at Israel’s largest paediatric hospital, the Company has been rapidly expanding into global markets, most recently launching their proprietary Healthy Height shake range in Chemist Warehouse and on T-Mall Global in China. 

The most recent 12 month, randomised, double- blinded and placebo controlled study evaluated the effects of the formula on 160 healthy but lean and short, pre adolescent males between the ages of 10-14.5 years old. The study was carried out in two phases- the first, a double-blinded administration of nutritional formula or placebo, followed by an open-label extension of the study with the nutritional formula given to all participants. 

The results showed a notable increase in the weight, BMI and muscle mass of participants who consumed Healthy Heights Grow Daily Boys 10+ over six-months, compared to those consuming the placebo. 

Interestingly, children over 11.4 years who participated in the study maintained their height increase rate, however children taking the placebo displayed a decrease in height increase rate.  

The dose of nutritional formula directly correlated with changes in growth. In short, it looks like this product really works. 

Lead researcher of the study, Dr. Michal Yackobovitch-Gavan commented: “ Intervention with a multi-nutrient, protein-rich formula was effective at increasing weight, fat-free mass, muscle mass, and BMI in short and lean pre-pubertal male adolescents. It also prevented the expected decline in height increase rate in older participants. All the participants were with no pubertal signs at the study entry. Hence, older participants were with delayed puberty as compared to their peers, and expected to grow slower as compared to children in the same age who already have begun their pubertal growth spurt. 

“This is a key trial that evaluated the importance of nutrition for pre-adolescents and is certain to inspire more research.” 

NGS CEO and Managing Director, Liron Fendell was encouraged by the findings, saying: “ As we launch Grow Daily Boys 10+ to market, it is great to have the clinical trial findings to verify the positive effect on growth for teen and pre-teen boys. 

“As we continue to build relationships with pharmacies and health food stores around the world, we also ensure they are equipped to educate buyers about what the trial findings mean and the best way to use the product for their child.  

“The make-up of nutrients required for optimal growth changes throughout a child;s growing years and this is why we created a formulation specifically for boys aged 10 and over. Our new Grow Daily Boys 10+ range contains all the essential micro nutrients, such as calcium and iron with high protein needed for optimal growth in pre-teens. 

“With both the Grow Daily Boys 10+ and Healthy Height product for children aged 3-9 officially proven to increase growth development in young people, we look forward to testing our formulas in different ways, such as our trials on children treating ADHD with stimulant medication, as well as on additional innovative products we look to bring to market.” 

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022
  •  
  •  
  •  
  •  
  • growth supplements
  • michael yackobovitch-gavan
  • ngs
  • nutritional growth solutions
  • paediatric nutrition
  • tmall
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Samantha Freidin
Samantha Freidin is a business journalist at Emerald Financial whilst also completing a Masters of Marketing and Digital Communications at Monash University.
Latest posts by Samantha Freidin (see all)
  • Aptar Pharma pulls the $7m trigger, recognising potential of Pharmaxis inhaler - August 5, 2022
  • Getting things from A to B isn’t as simple as it seems, until Yojee gets involved - August 4, 2022
  • NASDAQ biotech stocks have taken a hit, but this little Aussie biotech is quietly confident - August 3, 2022
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

Copyright © 2020 The Sentiment. All rights reserved.